Relmada Therapeutics, Inc. (RLMD) Cash Flow Statement
Relmada Therapeutics, Inc. (RLMD) generated -$46.0M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$46.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RLMDRelmada Therapeutics, Inc.Follow RLMD — free
—
Price chart with a free account
- Market cap
- 348.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2013 Dec 13 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.2 | -16.2 | -13.1 | -6.5 | -6.0 | -10.5 | -27.8 | -91.9 | -103.8 | -51.7 | -51.8 | -45.8 | -46.0 | |
| Capital expenditure | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | — | 182.1 | — | — | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -2.2 | -16.3 | -13.7 | -6.5 | -6.0 | — | -209.9 | — | — | — | -51.8 | -45.8 | -46.0 | |
| Stock-based compensation | 0.4 | 0.8 | 1.0 | 0.7 | 0.5 | 1.2 | 20.8 | 40.5 | 44.2 | 43.8 | 30.2 | 13.9 | — |
USD millions · SEC XBRL
Relmada Therapeutics, Inc. — questions
- What is Relmada Therapeutics, Inc.'s operating cash flow?
- -$46.0M over the twelve months to 2026-06-30.
- How much does Relmada Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- -$46.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Relmada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.